Breast Cancer

Triple-negative breast cancer patients treated with immune checkpoint inhibitors may experience a greater antitumoral immune response, according to a recent literature review. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized solid tumor malignancy treatment. ICIs target immunosuppressive receptors such as programmed cell death ligand 1 (PD-L1), programmed cell death 1 (PD-1), and cytotoxic T-lymphocyte-associated protein...

Elacestrant improves progression-free survival in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, especially in patients with estrogen receptor 1 gene mutations, according to the results of a recent literature review. Endocrine therapy is the backbone of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treatment. Most cases...

Racial disparities in curative intent surgery, endocrine therapy, and treatment-related adverse effects were seen among women with breast cancer in a recent single-center study. Breast cancer (BC) is the most common malignancy occurring worldwide among women. Racial disparities in BC outcomes and access to treatment are well documented, but there’s a lack of evidence regarding...

Oral selective estrogen receptor degraders are effective in the estrogen receptor 1 mutation subgroup of estrogen receptor-positive metastatic breast cancer, according to the results of a new study. Oral selective estrogen receptor degraders (SERDs) are novel agents used to treat estrogen receptor (ER)-positive metastatic breast cancer resistant to other hormonal agents. Elacestrant and camizestrant have...

Obesity is a risk factor for cancer recurrence in resected hormone-sensitive breast cancer patients undergoing adjuvant chemotherapy with aromatase inhibitors, according to a recent study. Aromatase inhibitors (AIs) are extensively used for treating hormone-sensitive breast cancer (BC). In post-menopause, estrogen is mainly formed in the adipose tissue via aromatase-mediated androgen conversion, which might impair the...

Pembrolizumab plus chemotherapy significantly improves survival in advanced triple-negative breast cancer expressing programmed death ligand 1, with a combined positive score of 10 or more compared to chemotherapy alone, according to a phase 3 trial. Triple-negative breast cancer (TNBC) lacks the expression of estrogen and progesterone receptors and involves overexpression of human epidermal growth factor...

Neoadjuvant chemotherapy in combination with nab-paclitaxel and pembrolizumab shows promising pathological complete response rates. Pembrolizumab (pembro) is the only approved immune checkpoint inhibitor for the neoadjuvant treatment of early triple-negative breast cancer (TNBC). It was introduced in combination with carboplatinum/paclitaxel and anthracycline/cyclophosphamide chemotherapy. Nab-paclitaxel (nP), although not approved, is also effective in TNBC.  A study...

Episode 1: Promoting Breast Health Equity   With guest Laura Crandon, Founder and President of Touch4Life   Transcript: [00:00] LC: “So really to take what some would call a tragedy given my metastatic condition and take that and turn it into a triumph so other people can learn from what I’ve been through.” LW: Hello,...

The place of care—whether a hospital or a doctor’s office—may have a profound impact on the quality and type of breast cancer care, as well as the reported side effects. One study reports disparities in breast cancer treatments and side effects between African American and White women. White women experience breast cancer more frequently, but...